Averto Medical Debuts with Oversubscribed $30M Series A Financing to Advance Innovative Medical Device that Avoids Need for Ostomy• Cormorant Asset Management leads financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and others

Averto Medical首次以3000万美元的超额认购A系列融资推出，以推进创新医疗设备，避免造口术的需要•鸬鹚资产管理公司在Venrock Healthcare Capital Partners、LifeSci Venture Partners、CVF等公司的参与下领导融资

• Ken Song, MD joins as Executive Chairman with Dan Puckett and Bihua Chen also joining the Board of DirectorsSAN FRANCISCO, May 7, 2024-- Averto Medical Inc ('Averto', 'The Company'), a clinical-stage medical device company pioneering minimally invasive gastrointestinal care, today announced the closing of an oversubscribed $30.5 million Series A financing.

•医学博士肯·宋（Ken Song）担任执行主席，丹·普克特（Dan Puckett）和陈碧华（Bihua Chen）也加入董事会。2024年5月7日，旧金山-Averto Medical Inc（“Averto”，“the Company”）是一家开创微创胃肠道护理的临床阶段医疗器械公司，今天宣布结束了一笔3050万美元的超额认购a系列融资。

Cormorant Asset Management led the financing with participation from Venrock Healthcare Capital Partners, LifeSci Venture Partners, CVF, and other investors..

鸬鹚资产管理公司在Venrock Healthcare Capital Partners、LifeSci Venture Partners、CVF和其他投资者的参与下领导了融资。。

The financing will support advancing Averto Medical's clinical testing of the ColoSeal™ Intraluminal Diversion System towards regulatory approvals. ColoSeal™ has the potential to help over 100,000 patients annually who undergo colorectal surgeries by avoiding the need to create an invasive temporary diverting ostomy.

这笔资金将支持Averto Medical对ColoSeal™腔内分流系统进行临床测试，以获得监管部门的批准。ColoSeal™通过避免创建侵入性临时分流造口术，每年有可能帮助超过100000名接受结直肠手术的患者。

Early clinical data has already shown promising results to address this multi-billion dollar market opportunity..

早期的临床数据已经显示出有希望的结果，可以解决这一数十亿美元的市场机会。。

In connection with this financing, Averto Medical further announced that Ken Song, MD will serve as Executive Chairman with Dan Puckett and Bihua Chen joining the board of directors. Dr. Song is a physician scientist and serial entrepreneur who has successfully led several companies (Ariosa Diagnostics, Omniome, RayzeBio) across the life sciences space resulting in several launched products and over $5 billion in realized company value via acquisitions.

关于此次融资，Averto Medical进一步宣布，医学博士Ken Song将担任执行董事长，Dan Puckett和Bihua Chen将加入董事会。宋博士是一位医学科学家和连续企业家，他成功领导了多家公司（Ariosa Diagnostics，Omniome，RayzeBio）跨越生命科学领域，推出了多个产品，通过收购实现了50多亿美元的公司价值。

Mr. Puckett was most recently Chief Financial Officer at Shockwave Medical, Inc. He helped lead Shockwave from a pre-commercial stage private company through its initial public offering in 2019, growing revenue to $730 million in 2023 and a multi-billion dollar market capitalization. Ms. Chen is Portfolio Manager for Cormorant Asset Management, a healthcare focused investment fund with over $2 billion under management that has supported numerous successful companies from inception to exit..

Puckett先生最近担任Shockwave Medical，Inc.的首席财务官。2019年，他帮助Shockwave从一家商业化前的私人公司通过首次公开募股（IPO）领导公司，2023年收入增长至7.3亿美元，市值达到数十亿美元。陈女士是鸬鹚资产管理公司（Cormorant Asset Management）的投资组合经理。鸬鹚资产管理公司是一家专注于医疗保健的投资基金，管理资金超过20亿美元，从成立到退出，为众多成功公司提供了支持。。

'Averto Medical is developing a medical device to avoid the need for ostomy, which is a debilitating procedure,' said Dr. Song. 'As a former gastroenterologist that has taken care of patients with ostomies, the value proposition of ColoSeal™ for patients, providers, and payers is crystal clear. I felt compelled to become involved to work with the team to progress the device through clinical studies and ultimately approval.'.

宋博士说，Averto Medical正在开发一种医疗设备，以避免造口手术，这是一种使人衰弱的手术作为一位曾经照顾造口患者的前胃肠病专家，ColoSeal™对患者，提供者和付款人的价值主张非常明确。我觉得有必要与团队合作，通过临床研究并最终批准该设备。”。

'I am thrilled to welcome this esteemed group of investors as well as Ken, Dan and Bihua to our board. We are committed to substantially improve the clinical care and outcome for patients undergoing colorectal surgeries,' said Kenton Fong, MD, Founder and Chief Executive Officer of Averto Medical.

“我很高兴欢迎这群受人尊敬的投资者以及肯、丹和碧华加入我们的董事会。Averto Medical创始人兼首席执行官Kenton Fong医学博士说，我们致力于大幅改善接受结直肠手术的患者的临床护理和预后。

About Averto Medical:

关于Averto Medical：

Averto Medical, Inc., formerly known as Savage Medical, Inc., is a clinical-stage medical device company dedicated to transforming gastrointestinal care. Its first product, the ColoSeal™ Intraluminal Colonic Diversion System enables procedures such as colorectal cancer resection without the need to create an invasive temporary diverting stoma.

Averto Medical，Inc.，原名Savage Medical，Inc.，是一家临床阶段医疗器械公司，致力于改变胃肠道护理。它的第一个产品ColoSeal™腔内结肠转移系统可以进行诸如结直肠癌切除术等手术，而无需创建侵入性临时转移造口。

Averto Medical is backed by a syndicate of leading healthcare institutional investors. For more information, visit the company's website at www.avertomed.com.Contact: .

Averto Medical由领先的医疗机构投资者组成的财团提供支持。有关更多信息，请访问公司网站www.avertomed.com.Contact：。。